LY3305677 for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests LY3305677 (also known as Mazdutide, IBI362, or OXM-3), a new treatment to assess its safety and tolerance in individuals with obesity or overweight. Researchers will administer injections under the skin and observe the drug's interaction with the body. The trial includes a placebo group for comparison. It seeks participants who are generally healthy, have maintained stable weight for 3 months, and have a body mass index between 27 and 50. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive it.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is there any evidence suggesting that LY3305677 is likely to be safe for humans?
Research has shown that LY3305677, also known as mazdutide, is generally well-tolerated. Studies have found its safety profile similar to other drugs used to manage weight and blood sugar levels.
In other trials, researchers tested mazdutide at different doses, and participants responded well. The most common side effects, such as nausea or an upset stomach, are usually mild and typical for this type of medication.
This treatment remains in the early testing stages, so researchers continue to gather detailed safety information. However, current data suggests it is safe for use, with manageable and expected side effects.12345Why do researchers think this study treatment might be promising?
Unlike the standard treatments for obesity and overweight, which often focus on lifestyle changes, medications like orlistat, or GLP-1 receptor agonists, LY3305677 is unique because it is administered subcutaneously. This delivery method might offer a more direct and potentially more effective way to manage weight. Researchers are excited about LY3305677 because it could offer a new mechanism of action, potentially leading to better outcomes for patients struggling with weight management. The excitement also stems from the possibility of addressing weight concerns with fewer side effects or complications compared to existing oral medications.
What evidence suggests that LY3305677 might be an effective treatment for obesity or overweight?
Research has shown that LY3305677, also known as mazdutide, could be a promising treatment for obesity. Studies have found that it works by activating two types of receptors in the body, aiding in weight reduction. In one study, many participants lost 10% or more of their body weight. Additionally, mazdutide helped control blood sugar levels, benefiting people with obesity. These findings suggest that LY3305677 could be an effective option for weight loss. Participants in this trial will receive either LY3305677 or a placebo to further evaluate its effectiveness.14678
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive injections of LY3305677 or placebo subcutaneously
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- LY3305677
- Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University